Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(5S)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3‑oxazolidine‑2,4‑dione is a synthetic small molecule with the molecular formula C16H12F2N2O3 and a molecular weight of approximately 318.27 g/mol[1][2][7]. It is classified as an oxazolidinedione derivative. The compound has been referenced in chemical and drug databases as an experimental agent but lacks detailed published information on its pharmacological activity or clinical development. There are no known approved indications or established mechanisms of action for this molecule in humans[1][2][8]. Its structure features a chiral center at the 5-position and contains both difluorophenyl and aniline moieties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (5S)-3-anilino-5-(2,4-difluorophenyl)-5-methyl-1,3-oxazolidine-2,4-dione.